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Abstract
Urticarial vasculitis (UV) is a small vessel vasculitis and an immune-complex mediated 
disease like other leukocytoclastic vasculitis. UV seems similar to common urticaria 
clinically. Major difference between urticarial vasculitis and urticaria is the duration of 
lesions. Urticarial lesions regress in 24 hours, but UV lesions persist longer than 24 hours. 
Residual hyperpigmentation, constitutional symptoms like fever, arthralgia, and abdom-
inal pain are other main clinical differences between these disorders. Upon confirmation 
of diagnosis, patients are divided into two major categories on the basis of serum comple-
ment levels: normocomplementemic UV (NUV) and hypocomplementemic UV (HUV). 
Consensus meeting in 1996 stated that long lasting (at least 24 hour–5 days) indurated 
wheals, which may be itchy, painful or tender, be associated with purpura and presence 
of associated extracutaneous findings, and cutaneous vasculitis confirmed by histopatho-
logical examination are defined as UV.
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1. Introduction
Urticarial vasculitis (UV) is an entity that is characterized by clinical presence of urticarial 
lesions and histopathological presence of vasculitis. Major difference between urticarial vascu-
litis and urticaria is the duration of lesions. Urticarial lesions regress in 24 hours, but UV lesions 
persist longer than 24 hours. Residual hyperpigmentation, constitutional symptoms like fever, 
arthralgia, and abdominal pain are other main clinical differences between these disorders [1]. 
UV lesions can be pruritic but more commonly these lesions are associated with symptom of 
burning. Skin biopsy shows histopathologic features of leukocytoclastic vasculitis [2]. Lesions 
usually persist for several months but very rarely they persist for years [3]. UV may be seen 
as a manifestation of a systemic disease or it may develop into a systemic illness by itself [2].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. Section
2.1. Epidemiology
UV is a rare condition and the exact incidence is not known as a result of small number of 
literature reports. UV frequency is reported to be between 2 and 20% in chronic urticaria 
patients and if histologic definition of vasculitis is used as a criterion for diagnosis then the 
estimate of the prevalence of UV in chronic urticaria patients becomes approximately 5% 
[1, 3, 4]. Approximately 80% of UV patients have underlying or associated disease [2]. UV is 
more common in women and very rare in children [4]. Case report of an infant with UV is the 
only case report presenting the literature [5]. The peak incidence of the disease is in the fourth 
decade of life [4].
2.2. Etiopathogenesis
UV is a small vessel vasculitis and an immune-complex mediated disease like other leuko-
cytoclastic vasculitis. Leukocytoclastic vasculitis is an example for type III immune reaction, 
which is characterized with circulatory immune complexes [6]. Initially antigen-antibody 
complex is formed in blood and then accumulation of the vessel walls. This complex reac-
tion leads to the activation of complement system by the classical pathway. Anaphylatoxins 
C3a and C5a induce mast cell degranulation and cytokine synthesis. Mast cells release tumor 
necrosis factor alpha (TNFα), prostaglandins, histamine, heparin, platelet activating factor, 
leukotrienes, neutrophil chemotactic factor A, neutral protease, and tryptase [6]. Increase in 
cytokine and chemokine production results in edema and tissue reaction. Main antibodies in 
this reaction are IgG or IgM, and rarely IgA. The antigen in the complex may be autologous 
or it may derive from exogenous origin such as an infection or drugs [4]. But the antigens are 
mostly not known [1]. Based on the level of complement, UV is divided into two subgroups: 
normocomplementemic UV (NUV) and hypocomplementemic UV (HUV) [7]. UV is often 
idiopathic, but in some cases, it can be triggered with drugs, infection (hepatitis B and hepa-
titis C), connective tissue disease, neoplasia, cold, and exercise. [3, 8–12]. Drugs were found 
to be responsible for 10% of UV patients. The risk of UV is irrespective of both dose and 
frequency [8]. Infliximab, procainamide, antidepressants, methotrexate, sulfamethoxazole-
trimethoprim, diltiazem, cimetidine, enalaprilin, and nonsteroid anti-inflammatory drugs 
(NSAIDs) are the main drugs reported in the literature [3, 13]. A patient with UV should 
also be examined for underlying diseases like viral infections, monoclonal gammopathies, 
serum sickness, and serum sickness like reactions, SLE, Sjögren’s syndrome (SS) or mixed 
cryoglobulinemia [2, 14, 15]. Polycythaemia rubra vera [16], essential thrombocythemia [17], 
systemic sclerosis [18], acquired reactive perforating collagenosis [19], lymphoma [20], leu-
kemia [21, 22], and thyroid dysfunction [23] are the other systemic diseases reported in the 
literature. UV patients with normal serum complement levels have rarely systemic manifesta-
tions. By contrast, UV patients with decreased C3 and C4 have systemic diseases including 
lung, kidney, and eye involvement [14]. At the same time, HUV patients may have extracu-
taneous symptoms like fever, myalgia, malaise, fatigue, arthralgia, conjunctivitis, episcleritis, 
nephritis, and cardiac valve involvement [8, 24]. A small group of patients with HUV also 
A Comprehensive Review of Urticaria and Angioedema62
have anti-C1q antibodies (anti-C1q Ab), and this group is considered as a separate entity 
called HUVS [7]. Ig G autoantibodies to the collagen like region of C1q (anti-C1q Ab) were 
detected in HUVS patients’ serum. Anti-C1q Abs were also detected in patients with systemic 
lupus erythematosus (SLE) and 85% of these patients had glomerulonephritis. Anti-C1q Ab is 
associated with glomerulonephritis in SLE patients [2]. However, all HUVS patients have UV 
lesions and anti-C1q Ab, but only a group of SLE patients have UV lesions [2]. UV occurs in 
5–10% of SLE patients and 28–47% of SLE patients have anti-C1q Ab [14]. HUVS patients form 
a small fraction of idiopathic HUV group (less than 5%), and these patients may have gas-
trointestinal, neurologic, ophthalmologic, renal, and pulmonary involvement [7]. Pulmonary 
disease in patients with HUVS was first described in 1982 with an incidence of 50%. However, 
these patients had history of tobacco exposure. After this report, different incidences (15–
50%) were reported in HUVS patients. The exact mechanism of obstructive lung disease is not 
known but vasculitis of pulmonary capillaries, dysfunction of α 1 antitrypsin and binding of 
anti-C1q Ab to the surfactant proteins in pulmonary alveoli are the possible hypotheses for 
pathogenesis [14]. Renal disease was also reported in 20–30% of patients with HUVS [25].
2.3. Clinical features
UV is characterized by widespread urticarial lesions each lasting longer than 24 hours clini-
cally [12, 26]. Classically urticarial plaques of UV are persistent or long lasting (in 64% of 
patients more than 24 hours) (Figure 1) and may resolve with purpura (Figure 2) or hyper-
pigmentation (in up to 35% of patients) in comparison to common urticaria [12]. Lesions may 
Figure 1. Urticarial lesions on the dorsal trunk of 47 years old male that is present for a month. The histopathological 
examination revealed lymphocytic vasculitis and laboratory examinations yield a diagnosis of accompanying Sjögren 
syndrome.
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be  asymptomatic, are usually pruritic and sometimes painful, tender or burning (in 33% of 
patients) in comparison to intensely pruritic urticarial lesions (Table 1) [12, 27]. UV presents 
usually with classical wheals but rarely livedo reticularis or even bullae may develop [12]. 
Angioedema can sometimes accompany urticarial lesions in up to 42% of UV patients [4, 12]. 
In a study reported it was detected that angioedema was present in 13% of HUV and 23% of 
NUV cases [28]. Following angioedema, a residual bruising may develop [12]. Typically clinical 
lesions of UV are recurrent and persist for more than 4–6 weeks even years [27]. As there are dif-
ferent clinical presentations of UV lesions, a biopsy is crucial in establishing a definite diagnosis 
[12]. All patients show histopathological evidence of leukocytoclastic vasculitis on biopsy [28].
Clinical characteristic UV Common urticaria
Lesion predilection Dependent areas, areas under focal 
pressure, anywhere
Anywhere
Symptoms Painful, tender, burning, pruritic Intensely pruritic
Persistence More than 24 hours [usually 24–72 
hours]
Less than 24 hours [usually 30 minutes–24 
hours]
Residual signs Purpura or hyperpigmentation None
Table 1. Clinical characteristics of cutaneous lesions of UV in comparison with common urticaria.
Figure 2. Widespread urticarial lesions with central purpura located on left lateral thigh of 85 years old female patient.
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Upon confirmation of diagnosis, patients are divided into two major categories on the basis 
of serum complement levels: normocomplementemic UV (NUV) and hypocomplementemic 
UV [HUV] cases [28]. Many UV patients have NUV [27]. UV patients also frequently present 
with systemic manifestations (Table 2) [26]. The most commonly observed systemic manifes-
tation of UV is termed as “AHA syndrome”: arthralgias and arthritis, hives and angioedema 
[12]. Like in the situation of cutaneous lesions, common urticariais still in the differential 
diagnosis of systemic manifestations of UV as common urticariacan rarely has angioedema 
and systemic symptoms like arthralgia or abdominal pain [12]. Systemic manifestations of 
UV develop mostly in hypocomplementemic patients [12]. HUV patients frequently have an 
underlying systemic disease [26, 29]. Systemic manifestations of HUV patients occur regard-
less of being idiopathic (primary HUV) or associated with an underlying disease (secondary 
HUV) [12]. Clinical features of UV can exacerbate with some situations like emotional stress, 
anxiety, exercise, and excessive alcohol consumption [12]. Additionally, heat and spicy 
foods can increase the pruritus and/or urticarial lesions [30]. UV lesions can develop under 
pressure of tight and narrow clothing [30]. Smokers can develop more severe respiratory 
involvement and progression to COPD in HUV patients [31]. UV can sometimes develop in 
striae distensae and can present a diagnostic challenge in pregnancy [13]. UV can sometimes 
be a presenting sign of SLE or present with a clinical picture similar to SLE [12, 28]. Some 
patients have autoimmune idiopathic HUV with a lupus-like clinical picture, hence termed 
HUVS [2, 27]. HUVS patients usually have accompanying systemic involvement involving 
more than one organ system [26]. These patients presenting clinically as HUVS are mostly 
young women and many aspects of the clinical picture are similar to SLE [12, 28]. Schnitzler 
syndrome is another clinical condition related to UV [32]. It is defined as the presence of UV 
in association with mostly IgM monoclonal gammopathy and increased markers of systemic 
inflammation [32].
Occurrence Systemic features
Common Musculoskeletal: arthralgia, arthritis
Less common Respiratory: cough, dyspnea, hemoptysis, COPD, asthma, pleural effusion
Renal disease: hematuria, proteinuria, glomerulonephritis
Gastrointestinal: substernal pain, abdominal pain, nausea, vomiting, diarrhea
Rare Cardiac: pericarditis, pericardial effusion, cardiac tamponade
Ophthalmologic: conjunctivitis, episcleritis, uveitis, geographic serpiginous 
choroidopathy, visual loss
Other: fever, splenomegaly, lymphadenopathy, cold sensitivity, reversible tracheal 
stenosis
Very rare CNS: pseudotumor cerebri, cranial nerve palsies, aseptic meningitis
Miscellaneous: transvers myelitis, cardiac valve disease, optic atrophy, Jaccaud’s 
syndrome [chronic postrheumatic fever arthropathy], peripheral neuropathy, 
pleuritis
Table 2. Clinical features of systemic involvement in UV.
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Patients can present with general constitutional symptoms, like fever, arthralgias, mal-
aise, and fatigue [12]. Most UV patients have musculoskeletal involvement presenting as 
arthralgia or arthritis [12, 26, 28]. Jaccoud’s syndrome or arthropathy was defined as joint 
deformities similar to that of rheumatoid arthritis [12]. It consists of ulnar deviation of the 
fingers, swan neck deformities and subluxations in the hands [12]. This hand deformity is 
most commonly associated with SLE and rarely with HUV [12]. Ophthalmologic involve-
ment is rare (10% of UV patients) and can present as conjunctivitis, episcleritis, uveitis, or 
geographic serpiginous choroidopathy leading to visual loss [12]. Eye involvement in the 
form of episcleritis and uveitis can develop mostly in HUV patients (21%) [28]. Pulmonary 
involvement may present clinically as cough, dyspnea, hemoptysis, COPD, asthma, pleu-
ritic, emphysema, or pleural effusion [12]. HUVS patients presenting with COPD are usually 
young smokers, and the observed COPD is more severe than that seen in heavy smoker 
patients without HUVS [12]. Emphysema can develop in UV patients as a result of leuko-
cytoclastic vasculitis of pulmonary vessels. Lung involvement may present clinically late in 
the disease process but is a leading cause of morbidity and mortality [12]. Renal disease can 
occur in 5–10% of patients with HUVS and is discovered by finding proteinuria and micro-
scopic hematuria [12]. Renal involvement can present as glomerulonephritis in 20–30% of 
HUV cases [12]. Gastrointestinal involvement can present clinically as nausea, vomiting, 
substernal pain, abdominal pain, diarrhea, or general feeling of gastrointestinal distress [12]. 
Cardiac involvement can develop rarely [12]. Recurrent pericarditis, pericardial effusion, 
cardiac tamponade, and cardiac valvular disease have been reported [12]. Several HUVS 
patients with Jaccoud’s arthropathy were reported to develop valvular heart disease requir-
ing valvular replacement [12, 24, 33, 34]. Central and peripheral nervous systems can rarely 
be affected [12].
2.4. Diagnosis
Consensus meeting in 1996 stated that long lasting (at least 24 hour–5 days) indurated wheals, 
which may be itchy, painful, or tender, be associated with purpura and presence of associated 
extracutaneous findings, and cutaneous vasculitis confirmed by histopathological examina-
tion are defined as UV [35]. UV should be suspected in any patient with urticarial lesions last-
ing more than 24 hours. The prevalence of UV among all patients that present with urticarial 
lesions is 11% and among patients with chronic urticaria it is 15–20% [23, 36, 37]. To ascertain 
the exact duration of urticarial lesions, a particular lesion could be encircled with a marking 
pen and the patient is re-examined 24 hour later to confirm the persistence of urticarial lesions 
[23]. Diascopy and dermatoscopy can help to suspect UV [23, 38]. The lesions of UV may be 
non- or partially-blanchable on diascopic examination [23, 38]. It was termed as “disappear-
ing halo test” in which upon diascopy clinically invisible purpura becomes evident as dark 
red or slightly brown macule in the center of a blanched UV lesion [38]. UV can disclose 
purpuric dots or globules in a patchy orange-brown background dermatoscopically corre-
sponding to extravasation and degradation of red blood cells due to leukocytoclastic vascu-
litis [39–41]. These purpuric dots are reddish initially and later they become more purplish 
[40]. Conversely, urticarial lesions disclose prominent and sometimes reticular red lines cor-
responding to ectatic and horizontal subpapillary vessels [39–41]. Definitive diagnosis of UV 
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requires a lesion biopsy demonstrating typical histopathological features in addition to the 
previously described clinical characteristics in a patient presenting with urticarial lesions [4]. 
Two lesion biopsies, one for routine histopathology and one for direct immunofluorescence, 
should be obtained [2]. Biopsies should be taken from the early lesions, which are maximum 
24–48 hours old [42]. Multiple biopsies may be required to establish a biopsy [42]. In the case, 
an UV diagnosis is made, the physician should additionally search for the presence of any 
underlying infectious etiology [43, 44]. The major finding to be searched for is the presence or 
absence of hypocomplementemia [2]. It was previously reported that 53–82% of UV patients 
have normal complement levels and hence NUV, 18–47% of UV patients have decreased 
complement levels and hence HUV [28, 45]. Approximately, 65% of HUV and 45% of NUV 
patients have systemic involvement [23]. Hypocomplementemic patients are rare (10–20% 
of all UV patients) and more likely to have systemic involvement and hence they should 
be appropriately investigated [23, 28, 42, 46]. Optimal classification of UV patients should 
be done by multiple (two to three) measurements of C1q, C3, C4, and CH50 during clini-
cal observation of several months duration [2]. Measurements should be done during active 
and quiescent periods [2]. Rare patients with HUVS may have cardiac valvular incompetence 
with/without Jaccoud’s arthropathy [24, 33, 35, 47]. In 1973, criteria to diagnose HUVS have 
been proposed [48]. A patient is diagnosed to have HUVS if he/she has two major and at least 
two minor criteria (Table 3) [48].
2.5. Laboratory examinations
A patient diagnosed to have UV should be appropriately tested [2]. Complete blood count, 
ESR, renal and liver functions, urinalysis, ANA, complements, should be examined in all cases 
with appropriate clinical findings of UV [2]. A scheme would be helpful for planning the labo-
ratory examinations in all patients with clinical UV presentation and specialized tests should 
be performed in some patients who have clinical clues of systemic involvement [30]. Once 
• Two major criteria
• Chronic urticarial eruption
• Low levels of complements
• At least two minor criteria
• Leukocytoclastic vasculitis
• Arthralgia/arthritis
• Ocular involvement [episcleritis or uveitis]
• Renal involvement [glomerulonephritis]
• Recurrent abdominal pain
• Presence of anti-C1q antibody
Table 3. Proposed criteria for diagnosing HUVS.
Urticarial Vasculitis
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basic diagnostic evaluation has been performed, additional laboratory examinations should 
not be so extensive and should be directed with regard to clues in the history and physical 
examination [30]. Hematologic examinations can reveal anemia and leukocytosis in nearly 
half of the patients [49]. Patients with positive anti-C1q antibodies have been detected to have 
more frequent HUVS, angioedema, livedo reticularis, musculoskeletal, ocular and kidney 
involvement, and less frequent gastrointestinal and pulmonary involvement than patients 
without anti-C1q antibodies [46]. These anti-C1q autoantibodies may sometimes be detected 
in patients having SLE, Good-pasture syndrome or idiopathic membranoproliferative glo-
merulonephritis without showing signs of urticarial vasculitis [4, 50, 51]. A case having circu-
lating immune complexes and a positive autologous serum skin test was also reported [52]. 
There are numerous reported cases who were associated with gammopaties and so patients 
should be appropriately evaluated [53–56]. Soluble serum vascular endothelial-cadherin is 
detected in systemic vasculitis cases in the acute period, and this can be used as a marker for 
endothelial cell damage and inflammatory response, but this is nonspecific for UV [57].
2.6. Histopathology
A lesional biopsy demonstrating the features of UV is the gold standard for diagnosis [4]. 
The key histopathologic feature is leukocytoclastic vasculitis affecting dermal capillaries and 
postcapillary venules (Figure 3) [2, 4]. Inflammation is located within the vessel walls and 
perivascularly [4]. Cellular infiltrate is primarily composed of neutrophils, rarely eosinophils, 
and lymphocytes may take place (Figure 4) [4]. Lymphocytes predominate in lesions older 
Figure 3. Superficial perivascular infiltration and leukocytoclastic vasculitis [Hemotoxylin & Eosin, original magnifi-
cation ×100] [Courtesy, Onat Akin, MD].
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than 48 hours [23]. In a study, 86% of specimens showed lymphocytic vasculitis, probably 
due to the age of the lesion biopsied [58]. If these histopathological changes described for UV 
involve the capillaries and postcapillary venules of the deep dermal layers, subcutaneous 
tissue, and submucosal connective tissue layers then it is termed as angioedema [2]. Direct 
immunofluorescence examination shows deposition of immunoglobulins, complement, and/
or fibrinogen within and around vessel walls in 58–79% of cases [1, 4, 30, 46]. Basement mem-
brane positive immunofluorescence examination is more frequent in HUV (70–96%) patients 
than in NUV (1–18%) patients [1]. However, the presence of basement membrane staining in 
a hypocomplementemic patient may suggest the diagnosis of SLE [30].
2.7. Differential diagnosis
The main differential diagnosis of UV is common urticaria [42]. The lesions in urticaria typically 
resolves in minutes to hours, migrates continually, and leaves no residual pigmentation after 
resolving in contrast to UV [42]. The main symptom in urticaria is the presence of intense pru-
ritus, UV lesions may present with a more burning sensation [2]. Indurated urticarial lesions 
of UV are indistinguishable especially from that of chronic spontaneous urticaria [4]. Urticaria 
lesions may be huge and are usually larger than those of UV [2]. Chronic urticarial lesions are 
clinically more indurated than that of acute urticaria [4]. Eleven percent of all patients present-
ing with urticarial lesions are found to have UV [23]. In cases of chronic and antihistamine 
unresponsive chronic urticaria, when biopsies of lesions were performed, 15–20% of patients 
were found to have histopathological features of UV and hence diagnosed as UV [36, 37]. So 
performing a biopsy is necessary to differentiate exactly these two conditions. When patients 
Figure 4. Small vessel vasculitis with neutrophilic infiltration and leukocytoclasia [Hemotoxylin & Eosin, original magnifi-
cation ×400] [Courtesy, Onat Akin, MD].
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with acute urticaria are biopsied, histopathology shows sparse cellular infiltrate and moderate 
to intense dermal edema [4]. Lesions of UV are usually smaller than ordinary urticaria and 
never present with annular lesions [38]. Additionally ordinary urticarial lesions are more pink-
ish than darker reddish lesions of UV [38]. In addition, UV lesions tend to be located more on 
dependent areas of the body [38]. Serum-sickness is a type-III hypersensitivity reaction that 
develops for example against horse-serum diphtheria antitoxin and can present with urticarial 
lesions [59]. Serum-sickness like reaction is a similar clinical entity triggered by drugs or infec-
tions [59]. Urticaria multiforme presents with annular lesions and acral edema or angioedema, 
mostly triggered by viral infections [59]. Both are self-limited and have favorable long-term 
prognoses [59]. Acute infantile hemorrhagic edema is another self-limited disorder that should 
be remembered in differential diagnosis of hemorrhagic urticarial lesions in pediatric cases 
[59]. Henoch-Schönlein purpura can present with urticarial lesions and should be searched 
for especially in pediatric cases with renal and/or gastrointestinal and/or arthritic involvement 
[59]. Urticarial arthritis is a condition observed in HLA-B51 positive patients, presenting with 
arthritis, urticaria (lasting less than 24 hours), and facial angioedema [49]. Some of the patients 
may show a biopsy with leukocytoclastic vasculitis some only leukocytic infiltration with-
out vasculitis [49]. Acquired angioedema should be differentiated from HUV associated with 
angioedema and both disorders have decreased complement levels. Pruritic urticarial papules 
and plaques of pregnancy is the main differential diagnosis when UV develops in the preg-
nancy, especially in the striae distensae [60]. Likewise erythema multiforme, bullous pemphi-
goid, sweet’s syndrome, and urticarial pigmentosa can be added to the differential diagnoses 
of UV [27].
Auto-inflammatory diseases are a group of rare hereditary monogenic disorders of innate immu-
nity with presenting symptoms of fever and inflammatory, sometimes urticarial, skin lesions [3, 
61, 62]. Auto-inflammatory diseases usually cause a familial life-long disease that starts in child-
hood in hereditary fever syndromes [62]. Auto-inflammatory syndromes cause flatter wheals 
and erythematous patches without surrounding flare and they last hours and even up to 24 
hours and are accompanied by burning sensation rather than itching and they may be pain-
ful [62]. Lesions do not give any response to antihistamines and are associated with systemic 
symptoms of fever, fatigue, and arthralgia [62]. Very recently, vasculitis has been described his-
topathologically in three cases of auto-inflammatory diseases [61]. Hence, the clinician should 
take into account the rare possibility of auto-inflammatory associated vasculitis presenting with 
urticarial lesions and fever in the differential diagnosis of UV [61]. Some autoimmune disorders 
like SLE, Sjögren syndrome, dermatomyositis, or rheumatoid arthritis may present clinically 
with urticarial lesions [3]. Histopathological findings of UV are not specific in general and simi-
lar histopathological findings can be seen in SLE [42]. It is still unclear that HUVS is a similar 
disease to or a subtype of SLE [12, 28, 48, 63]. Both diseases share similar clinical findings and 
can present together [12, 28, 48, 63]. So when a patient is diagnosed as HUVS, he/she should 
also be evaluated for SLE [48]. Other systemic vasculitides may present clinically with urticarial 
lesions [3]. Rarely polyarteritis nodosa and Churg-Strauss syndrome may present clinically with 
urticarial lesions [3]. Some hematologic malignancies (lymphoma or gammopathies) and hema-
tologic disorders (polycythemia vera and thrombocythemia) can also present clinically with urti-
carial lesions [3, 16, 17]. Other rare syndromes like PAPA, Blau, or Majeed syndromes can also 
present clinically with urticarial lesions [3].
A Comprehensive Review of Urticaria and Angioedema70
2.8. Treatment
In any given patient with UV, if an underlying condition is present, it must be treated initially 
[2, 42]. Different degrees of clinical severity of the disease preclude proposal of any standard 
form of therapy [30]. Therefore, there is no universal therapy and variation in individual 
response to any form of therapy that exist [30]. In general, the more severe the systemic 
involvement (as in HUVS) is, the more challenging it becomes to treat the disease [42]. The 
most difficult patient to treat is the one who develops COPD or has established COPD in the 
setting of HUVS [2]. COPD in HUVS develops more frequently and most severely in patients 
who smoke, so patients should give up smoking and also avoid inhaling second-hand smoke 
[31]. One case has been reported to go into remission with an elimination diet [64]. This case 
may show the possibility of pseudoallergens’ role in the etiopathogenesis of UV and similar 
to chronic urticaria treatment a pseudoallergen-free diet can be tried in selected cases. 
Antihistamines are helpful for the symptomatic control of pruritus in all patients and may be 
sufficient for the therapy of mild cutaneous UV without systemic involvement [4, 30]. 
However, antihistamines do not affect immune-complex-mediated inflammation and hence 
do not alter the course of the disease [4]. Cinnarizine, an antihistaminic used for Meniere’s 
disease and car sickness, was found to be effective in UV patients [36]. A brief course of sys-
temic corticosteroids may be useful to control intermittent exacerbations of UV, with both 
cutaneous and systemic involvement [4]. However, a dose of systemic corticosteroids up to 40 
mg/day of prednisolone may be needed [30]. Long-term use is limited by the well-known side 
effects of corticosteroids and they should only be used in cases who are intolerant to or unre-
sponsive to other alternative drugs [30]. A variety of alternatives to corticosteroids are used in 
the treatment of milder forms of UV [4]. These alternatives include indomethacin, colchicine, 
and dapsone that are commonly used in the clinical practice [4]. NSAIDs like indomethacin 
may help approximately half of patients with minimal disease [42]. Indomethacin use is usu-
ally discontinued or restricted by its gastrointestinal adverse effect potential, like upset stom-
ach [4, 42]. In some unfortunate patients, NSAIDs can even cause UV or exacerbation of the 
existing UV [30]. Dapsone is a sulfone and shows more effectiveness than other alternatives in 
the treatment of UV [4]. Dapsone may work synergistically with pentoxifylline [4]. The mech-
anism of action of dapsone is poorly understood in the treatment of UV [4]. Before commenc-
ing on dapsone treatment, serum levels of glucose-6-phosphate dehydrogenase enzyme 
should be measured as deficiency of it results in severe hemolysis with dapsone usage [4]. 
Headache, nonhemolytic mild anemia and most importantly agranulocytosis may develop 
less frequently [4]. Hence, monitorization of complete blood count should be performed peri-
odically in patients who use dapsone [4]. Patients having UV in the clinical setting of SLE or 
lupus-like disorder may have a more favorable response to treatment with dapsone [4]. 
Antimalarials like hydroxychloroquine have been reported to be effective in approximately 
50% of patients with only cutaneous involvement [4, 30, 52]. Colchicine is an alkaloid that 
inhibits neutrophil chemotaxis, generation of lysosomes and stabilizes lysosomal membranes 
[4, 65]. It has clinical efficacy in selected cases of UV [65]. Reserpine is an alkaloid extracted 
from the roots of the plant Rauwolfia serpentine [66]. Reserpine was once used for the treat-
ment of psychosis and hypertension [66]. It can be added to the antihistamines /corticoste-
roids in a dose of 0.3–0.4 mg thrice daily and reported to be helpful in majority of patients 
with UV [25, 66, 67]. If these alternative drugs do not get enough benefit or intermittent 
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 systemic corticosteroids do not control symptoms adequately then chronic systemic cortico-
steroid usage can be considered in milder forms of disease [4]. Higher dosage systemic corti-
costeroid treatment is necessary in the presence of hypocomplementemia or systemic 
involvement [4]. Systemic prednisone or equivalent is usually given at 1 mg/kg dose till clini-
cal remission, later the dose could be slowly tapered [4]. Systemic corticosteroids could be 
tapered and discontinued without relapse in some patients [4]. However, many patients do 
experience disease relapse and need chronic corticosteroid treatment [4]. In the case of inad-
equate systemic corticosteroid response or when unacceptable corticosteroid adverse effects 
do occur than second line treatment choices should be considered, like azathioprine or cyclo-
phosphamide [4]. In the resistant patients, systemic corticosteroids can even be effectively 
combined with dapsone, azathioprine, and cyclophosphamide [30]. In the chronic and resis-
tant subset of patients, corticosteroid-sparing immunosuppressive agents such as azathio-
prine, cyclophosphamide, cyclosporine A, or mycophenolate mofetil have been shown to be 
effective [4]. Azathioprine has been shown to be a useful adjunct to corticosteroids for stabili-
zation of renal and pulmonary function [4, 68]. Methotrexate has usually inconsistent and 
disappointing results in the treatment of UV [4, 24, 33, 69]. Methotrexate is typically effective 
in inflammatory myositis associated with HUVS [70]. Favorable clinical responses have been 
achieved with cyclophosphamide in corticosteroid-resistant UV cases [4, 71]. Cyclosporine A 
has provided favorable clinical efficacy in the treatment of HUVS, including cases that are 
resistant to cyclophosphamide [4]. Cyclosporine A has been shown to improve respiratory 
involvement in HUVS patients with improvements in the forced expiratory volume in one 
second (FEV1), the diffusing capacity of the lung for carbon monoxide (DLCO) and regression 
of leukocytosis in bronchoalveolar lavage (BAL) [2]. Cyclosporine A has also been shown to 
be effective in renal involvement associated with HUVS [72]. Mycophenolate mofetil has also 
been shown to be efficacious in the treatment and maintenance of patients with HUV/HUVS 
[24, 73, 74]. Gold injections were tried and found to be effective in UV as in rheumatoid arthri-
tis, but it is now a historical approach [75]. Plasmapheresis can provide rapid but temporary 
benefit in recalcitrant cases of UV [4, 76]. Plasma exchange has been shown to control symp-
toms rapidly during treatment but lesions recurred later in some patients [30, 76, 77]. High 
dose intravenous immunoglobulin (IVIG) also has been tried and shown to be effective in 
some recalcitrant HUVS cases [20, 78]. However, there are cases with inefficient response to 
IVIG [67, 79]. Rituximab can be used in refractory and/or relapsing or severe cases with pro-
longed duration of efficacy [46, 56, 80]. Anti-IL-1 blockage (anakinra, canakinumab) has 
shown promising results in the treatment of UV [81, 82]. However, these patients may have 
UV associated with auto-inflammatory diseases. A therapy-resistant SLE patient with UV 
lesions showed good response to IL-6 antagonist tocilizumab [83]. Omalizumab was used in 
a small number of NUV patients with success but some displayed a quick relapse following 
discontinuance [84, 85]. First line treatments used were determined to be mostly corticoste-
roids, hydroxychloroquine, and colchicine in decreasing order in a large retrospective study 
that involved only HUV patients [46]. Second and third line treatments given in this study 
were corticosteroids, hydroxychloroquine, and immunosuppressive agents in decreasing 
order [46]. In patients having hepatitis C infection, cryoglobulinemia and resultant UV, effec-
tive antiviral therapy (interferon-alpha and ribavirin) should be instituted [2]. Effective anti-
viral therapy has been shown to control HCV infection and cure UV in nearly half of these 
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patients [2, 86, 87]. However, if the antiviral treatment is stopped the UV lesions do recur [87]. 
Angioedema may develop at any time in the course of UV [31]. If angioedema develops and 
involves larynx, the initial treatment may be epinephrine [31].
2.9. Course and prognosis
UV is a complicated disease and it has an unpredictable course [12]. An individual can have 
lesions for weeks to many years continuously or intermittently [12, 30]. The average duration 
of the disease was found to be 3 years and disease could last up to 23 years [30, 42]. Response 
of patients with UV to any given treatment is variable [4]. The course of the idiopathic NUV 
is favorable overall and patients usually do not develop any other diseases or mortality in the 
follow up [12, 30]. The course of HUV and HUVS may be less favorable [12, 30]. Patients with 
HUV may need an additional add-on therapeutic after about a median of 8 months duration 
[46]. Musculoskeletal, ocular, and renal disease usually responds to systemic treatment without 
any long-term severe consequences [14]. After adequate therapy serum complements increase 
to or near to normal values and anti-C1q antibody titers decrease [14]. However, serum C1q 
levels remained below normal values even in the presence of complete remission [14]. UV pres-
ents clinically in a spectrum of disease severity from NUV to HUV to HUVS [42, 46]. However, 
there is no finding to support the presence of any transition from one to another in follow up 
of these patients [42]. The main causes of morbidity and mortality are pulmonary manifesta-
tions like COPD, cardiac manifestations and laryngeal edema in patients with HUVS [14, 30, 
31]. Precocious emphysema and COPD develop in patients with HUVS and especially in those 
patients who are moderate to heavy smokers [14, 88]. Onset of dyspnea heralds a poor out-
come in HUVS patients with pulmonary involvement [14]. Treatment usually did not appear 
to alter the progression of COPD [14]. Of these HUVS patients with chronic or recurrent dys-
pnea, 55% die of respiratory failure [14]. In this subset of patients bronchogenic carcinoma can 
also be seen and adds to the overall morbidity and mortality risk [46, 88]. Cardiac involvement 
with pericarditis or valvulitis and significant valvular damage may develop in rare cases with 
HUVS and may be progressive and fatal [24, 33, 34, 46]. As cardiac involvement may cause 
significant morbidity and mortality and as its frequency is unknown, all patients should be 
evaluated [89]. Angioedema develops in 51% of cases with HUVS and may be life-threatening 
if it involves larynx [31, 46]. Pediatric and young adult patients (onset of disease before age of 
30) may experience more renal involvement and show severe pulmonary complications and 
may have graver prognosis [89]. There may be significant morbidity resulting from involve-
ment of other organ systems. Rarely vasculitis can affect optic nerve and retina and hence can 
threaten vision [90]. All UV patients need to be evaluated ophthalmologically as 15–20% of all 
UV cases may have ocular involvement in the disease course [90]. A patient with Muckle-Wells 
disease with associated UV developed sudden bilateral sensorineural hearing loss and had 
modest outcome following cochlear implantation [91]. Gastrointestinal involvement can lead 
to ischemic ulceration in the bowel [30]. Renal involvement can lead to renal insufficiency, this 
is especially common in pediatric cases and should be promptly treated [30, 89].
There are other rare associated cutaneous findings in UV patients reported in the literature. 
A case with rapidly progressing acquired cutis laxa following involvement of the skin areas 
with lesions of NUV was reported [92]. A reported pregnant woman developed acquired 
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reactive perforating collagenosis at the sites of resolved UV lesions 3 weeks following the 
onset and treatment of UV [19]. A reported UV case developed acquired hemophilia follow-
ing 4.5 years of follow up [93]. Another reported NUV case first presented with acquired 
hemophilia and developed NUV and angioedema in the following 5 months [94]. Rarely 
inflammatory myositis can develop in HUVS cases despite ongoing immunosuppressive 
therapy [70]. Complement deficiency may lead to increased susceptibility to the infections 
with encapsulated bacteria, especially meningococcus [95]. As a result, a case of meningo-
coccal meningitis that developed in a patient with HUVS was reported [95]. The course of 
the UV may accompany the course of underlying disease. A paraneoplastic NUV case was 
reported to clear with chemotherapy for underlying chronic lymphocytic leukemia and dis-
ease recurred with the recurrence of underlying hematologic malignancy [21]. Three women 
with UV were evaluated in a study including 29 systemic vasculitis patients with 51 preg-
nancies to search for the outcome of pregnancy in systemic vasculitis [96]. The authors have 
found that the patients with a diagnosis of systemic vasculitis may have exacerbation of the 
vasculitic disease during pregnancy or following delivery, may have more pregnancy related 
morbidity like preeclampsia and may have a lower median gestational age [96].
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